Sangamo Therapeutics Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 16c, Revenues Miss
May 8, 2019 4:03 PM EDTSangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.41), $0.16 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $8 million versus the consensus estimate of $22.82 million.
"With recent encouraging clinical data in hemophilia A gene therapy and ex vivo gene-edited... More
